Amneal Pharmaceuticals stock hits 52-week high at 15.08 USD
Amneal Pharmaceuticals (AMRX) stock reached a new 52-week high of $15.08, reflecting substantial growth with a 92.55% increase over the past year and 56.83% in six months. Despite an InvestingPro analysis suggesting overvaluation with a high P/E ratio, analysts maintain a bullish outlook with price targets up to $18. Recent positive developments include FDA approvals for two denosumab biosimilars and an epinephrine injection, a partnership for a Parkinson's disease treatment, and inclusion in the S&P Dow Jones Indices.
Amneal Pharmaceuticals stock hits 52-week high at 15.08 USD By Investing.com
Amneal Pharmaceuticals' stock reached a 52-week high of $15.08, reflecting a 92.55% increase over the past year and a 56.83% gain in six months. Despite its strong performance, InvestingPro analysis suggests the stock might be overvalued, although analysts maintain a bullish outlook with price targets up to $18. Recent developments, including new FDA approvals and an upcoming inclusion in the S&P Dow Jones Indices, contribute to investor confidence and the company's growth potential.
How Investors Are Reacting To Amneal Pharmaceuticals (AMRX) Index Additions And Opioid Settlement Resolution
Amneal Pharmaceuticals faced an investment narrative shift with its inclusion in several S&P indices and the finalization of a nationwide opioid settlement. These developments are expected to increase investor visibility and reduce legal overhang. The focus for investors is now on the company's operating performance, cash generation, and balance sheet resilience, rather than potential litigation surprises.
If You Invested $100 In Amneal Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today
This article analyzes the performance of Amneal Pharmaceuticals (NASDAQ: AMRX) stock over the past five years. An investment of $100 five years ago would be worth $276.92 today, reflecting an average annual return of 22.74%. The article highlights the significant impact of compounded returns on investment growth.
Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi Year Run?
Amneal Pharmaceuticals (AMRX) has experienced significant stock growth over several years, leading investors to question its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 79.8%, with an intrinsic value of US$69.18 per share compared to its recent price of US$13.95. Additionally, its Price/Sales (P/S) ratio of 1.49x is below both the industry average and Simply Wall St's fair ratio of 2.99x, further indicating undervaluation.
Amneal Pharmaceuticals, Inc. Added to S&P SmallCap 600® Index
Amneal Pharmaceuticals, Inc. has been added to the S&P SmallCap 600® Index, effective January 30, 2026, a move that analysts believe reflects the company's consistent financial performance and increased visibility among investors. This inclusion is expected to enhance trading liquidity and broaden Amneal's investor base, recognizing its position as a global biopharmaceutical company focusing on a diverse portfolio of products. The company's executives expressed satisfaction with this recognition, highlighting its strategic importance for growth and investor awareness.
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
Amneal Pharmaceuticals, Inc. announced it will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before market open. The company will host an audio webcast at 8:30 a.m. ET, accessible through its Investor Relations website. Amneal, a global biopharmaceutical company, focuses on affordable medicines, specialty pharmaceuticals, and distribution for the U.S. federal government and other markets.
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Momentum
Amneal Pharmaceuticals (AMRX) has experienced notable share price momentum but a recent pullback. The stock appears undervalued based on a 1.4x Price to Sales ratio compared to peers and an estimated fair range, and a Discounted Cash Flow model suggests a significantly higher fair value of US$69.18 per share. Investors are encouraged to consider these valuation indicators alongside potential risks like slowing revenue growth or continued margin pressure in the competitive generics market.
Amneal Pharmaceuticals stock hits 52-week high at $13.48 By Investing.com
Amneal Pharmaceuticals (AMRX) stock reached a 52-week high of $13.48, reflecting strong market performance with a 62.35% total return over the past year. The company, with a market capitalization of $4.2 billion, has a "GREAT" financial health score and expects profitability this year. Recent FDA approvals for biosimilars and an epinephrine injection, along with a research collaboration for Parkinson's disease treatment, further highlight its growth and expansion.
Amneal Pharmaceuticals stock hits 52-week high at $13.48 By Investing.com
Amneal Pharmaceuticals (AMRX) stock recently hit a 52-week high of $13.48, reflecting a significant market performance with a 62.35% total return over the past year. The company boasts a market capitalization of $4.2 billion and strong financial health. Recent achievements include FDA approval for two denosumab biosimilars (Boncresa and Oziltus) and an epinephrine injection, alongside a research collaboration with KeifeRx for a Parkinson's disease treatment.
Amneal Pharmaceuticals stock hits 52-week high at $13.04
Amneal Pharmaceuticals (AMRX) stock recently hit a 52-week high of $13.04, reflecting a 63.58% rise over the past year and a 50.95% gain in six months. This surge is attributed to strategic initiatives, favorable market conditions, and strong investor confidence highlighted by a bullish analyst consensus. The company recently received FDA approvals for two denosumab biosimilars and an epinephrine injection, and reported positive interim results for its Parkinson’s disease treatment, CREXONT.
A Look At Amneal Pharmaceuticals (AMRX) Valuation As Analyst Optimism And Revenue Outlook Support Recent Momentum
Amneal Pharmaceuticals (AMRX) is experiencing positive momentum due to strong revenue growth, a positive earnings outlook, and strategic government contracts, with its stock performing well recently. Analysts believe the stock is currently undervalued by 5.3% at US$13.26, with a fair value estimated at US$14.00, driven by assumptions about product launches, cost management, and pipeline execution. The company's recent debt refinancing and anticipated tax benefits are expected to enhance financial flexibility and allow for reinvestment in high-growth areas like biosimilars, potentially boosting future earnings and free cash flow.
Amneal Pharmaceuticals stock hits 52-week high at $13.04 By Investing.com
Amneal Pharmaceuticals stock (AMRX) reached a 52-week high of $13.04, marking a 63.58% increase over the past year and 50.95% in six months, demonstrating strong investor confidence. The company's performance is supported by a solid current ratio of 2.13 and recent FDA approvals for two denosumab biosimilars and an epinephrine injection. Analysts predict profitability this year, although InvestingPro suggests the stock may be slightly overvalued.
Amneal Pharmaceuticals stock hits 52-week high at $13.04 By Investing.com
Amneal Pharmaceuticals Inc. (AMRX) stock reached a new 52-week high of $13.04, reflecting a significant 63.58% rise over the past year and a 50.95% gain in six months. The company's performance is supported by a strong current ratio and investor confidence, despite some InvestingPro analysis suggesting it's slightly overvalued. Recent positive developments include FDA approvals for two denosumab biosimilars and an epinephrine injection, as well as positive interim results from its Parkinson's disease treatment study.
Amneal Pharmaceuticals stock hits 52-week high at $13.04
Amneal Pharmaceuticals Inc. Class A stock recently reached a 52-week high of $13.04, reflecting a significant increase of 63.58% over the past year and 50.95% in the last six months. This performance is attributed to strategic initiatives and favorable market conditions, with the company demonstrating a strong current ratio and a bullish analyst consensus. Recent FDA approvals for biosimilars Boncresa and Oziltus, as well as an epinephrine injection, and positive Phase 4 study results for CREXONT, further highlight Amneal's expanding portfolio and investor confidence despite being considered slightly overvalued.
Amneal Pharmaceuticals stock hits 52-week high at $12.99 By Investing.com
Amneal Pharmaceuticals' stock (AMRX) recently reached a new 52-week high of $12.99, demonstrating significant market performance with a 65.92% increase over the past year. This achievement follows the FDA approval of two denosumab biosimilars and an epinephrine injection, expanding Amneal’s offerings, along with positive interim results from its Parkinson's disease treatment study. Despite being considered slightly overvalued, analysts maintain a "Buy" consensus, with price targets up to $15.
Amneal Pharmaceuticals stock hits 52-week high at $12.99
Amneal Pharmaceuticals Inc Class A stock recently reached a 52-week high of $12.99, demonstrating significant market performance with a 65.92% increase over the past year. This surge is supported by recent FDA approvals for two denosumab biosimilars and an epinephrine injection, alongside positive interim results from its Parkinson's disease study. Despite being considered slightly overvalued by InvestingPro analysis, analysts maintain a "Buy" consensus with price targets up to $15, reflecting confidence in the company's strategic initiatives and growth potential.
Amneal Pharmaceuticals stock hits 52-week high at $12.99 By Investing.com
Amneal Pharmaceuticals Inc. Class A stock recently reached a 52-week high of $12.99, nearly doubling its 52-week low, reflecting strong market performance and investor confidence. The company also announced FDA approvals for two denosumab biosimilars and an epinephrine injection, alongside positive interim results for its Parkinson's disease treatment, CREXONT. Despite a slight overvaluation according to InvestingPro, analysts maintain a "Buy" consensus with price targets up to $15, supported by solid financials and strategic growth initiatives.
Amneal Pharmaceuticals stock hits 52-week high at $12.99 By Investing.com
Amneal Pharmaceuticals stock reached a 52-week high of $12.99, nearly doubling its 52-week low, reflecting strong market performance and investor confidence. The company also announced FDA approvals for two denosumab biosimilars and an epinephrine injection, alongside positive interim results for its Parkinson's disease treatment, CREXONT. Despite concerns about slight overvaluation, analysts maintain a Buy consensus with price targets up to $15.
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
Amneal Pharmaceuticals, Inc. announced FDA approval for its denosumab biosimilars Boncresa™ (referencing Prolia®) and Oziltus™ (referencing XGEVA®). This expands Amneal's biosimilars portfolio to five commercial products, strengthening its position in the rapidly growing market for affordable medicines. The partnership with mAbxience underscores a commitment to expanding access to high-quality biologic medicines in the U.S.
Amneal Pharmaceuticals (AMRX): Valuation Check After FDA Approval for New Epinephrine Injection
Amneal Pharmaceuticals (AMRX) recently received FDA approval for its epinephrine injection, targeting a significant hospital therapy market. Despite a strong year-to-date share price return of approximately 62%, the article questions if the market has already factored in future growth. Simply Wall St's analysis suggests a fair value of $13.80, indicating a modest undervaluation, assuming the company can avoid generic price pressure and execute on its pipeline.
Amneal Pharmaceuticals stock hits 52-week high at $12.69
Amneal Pharmaceuticals stock reached a 52-week high of $12.69, reflecting significant momentum with a 60.71% one-year change and a 55.29% price return over six months. Despite trading above its Fair Value and a high P/E ratio of 769.57, analysts maintain a "Buy" consensus due to the company's "GREAT" financial health and recent FDA approvals for epinephrine injection, generic albuterol sulfate, and generic Restasis, alongside positive interim results for its Parkinson's treatment CREXONT.
Amneal Pharmaceuticals stock hits 52-week high at $12.69 By Investing.com
Amneal Pharmaceuticals (AMRX) stock has reached a new 52-week high of $12.69, reflecting a 60.71% increase over the past year and a 55.29% price return over the last six months due to increased investor confidence and growth prospects. Despite a high P/E ratio, analysts maintain a "Buy" consensus, supported by recent FDA approvals for epinephrine injection and generic albuterol sulfate, and positive interim results for their Parkinson's treatment, CREXONT.
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following FDA Green Light For Hospital Epinephrine
Amneal Pharmaceuticals recently received FDA approval for its epinephrine injection and reported positive interim data for its Parkinson’s therapy, CREXONT. These developments aim to strengthen Amneal's position by diversifying beyond traditional U.S. oral generics and entering higher-value neurology treatments. Despite these advancements, the company faces ongoing challenges from intense generic price pressure and high leverage, which investors need to consider.
A Look at Amneal Pharmaceuticals’ Valuation as New FDA Generics to Restasis and ProAir HFA Expand Growth Prospects
Amneal Pharmaceuticals (AMRX) recently received FDA approvals for generic versions of Restasis and ProAir HFA, opening up opportunities in multibillion-dollar markets. Despite recent share price dips, the company shows strong long-term momentum with a 90-day return of 24.12% and a 3-year total shareholder return of 419.13%. The stock is considered 11.6% undervalued with a fair value pegged at $13.50 against a recent close of $11.94, driven by expected growth in its biosimilars and generics portfolio.
Is It Too Late To Consider Amneal Pharmaceuticals After Its 425.4% Three Year Surge?
Amneal Pharmaceuticals has seen a significant surge of 425.4% over three years, with recent gains of 57.1% year-to-date and 8.9% over the last 30 days. Despite this growth, valuation checks by Simply Wall St suggest the stock is still undervalued, with a Discounted Cash Flow (DCF) analysis indicating an 82.4% discount and its Price-to-Sales (P/S) ratio of 1.31x being well below industry averages. The article encourages investors to explore "Narratives" on Simply Wall St's community page to derive their own fair value based on future projections.
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Key FDA Wins For Epinephrine And Complex Generics
Amneal Pharmaceuticals recently secured FDA approvals for its epinephrine injection and several complex generics, including cyclosporine ophthalmic emulsion (generic RESTASIS). These approvals are anticipated to shift Amneal's revenue mix towards higher-value injectables and ophthalmics, potentially generating billions in annual sales. While these developments strengthen the investment thesis, Amneal's high leverage and U.S. generics price pressure remain key factors for investors to consider.
Amneal stock rises after FDA approves epinephrine injection
Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) stock rose 2.8% in after-hours trading following FDA approval for its epinephrine injection USP. This approval expands the company's injectable medicine portfolio with single and multi-dose vials, addressing severe allergic reactions and hypotension in septic shock. The market for these injections was approximately $118 million in the U.S. for the 12 months ending October 2025.
Amneal stock rises after FDA approves epinephrine injection
Amneal Pharmaceuticals Inc Class A (NASDAQ:AMRX) saw its stock rise after the FDA approved its epinephrine injection USP. This expands the company's injectable medicine portfolio with both single-dose and multi-dose vials, addressing the need for emergency and acute care in hospitals. U.S. annual sales for epinephrine injection reached approximately $118 million for the 12 months ending October 2025, highlighting the market significance of this approval.
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
Amneal Pharmaceuticals announced positive interim results from its Phase 4 ELEVATE-PD study for CREXONT, showing significant improvements in "Good On" time and reductions in "Off" time for Parkinson's disease patients. The study highlights CREXONT's effectiveness in motor symptom control and longer duration of benefit compared to other oral therapies. These findings underscore CREXONT as a key therapeutic advancement in a field with limited innovation, with longer-term data expected in 2026.
FDA Approval for Generic Restasis Might Change the Case for Investing in Amneal Pharmaceuticals (AMRX)
Amneal Pharmaceuticals recently received FDA approval for its generic Restasis, a significant expansion of its ophthalmic therapies portfolio and expertise in sterile manufacturing. This approval strengthens Amneal's pipeline and differentiated generics strategy, targeting a key growth area in the US$2.00 billion annual dry eye disease market. While the milestone supports diversification, the company still faces risks from persistent margin compression due to generics pricing and buyer consolidation.
Amneal to Participate in Upcoming Investor Conferences
Amneal Pharmaceuticals, Inc. announced that its Co-Chief Executive and President, Chirag Patel, and Chief Financial Officer, Tasos Konidaris, will participate in the Piper Sandler 2025 Healthcare Conference and the J.P. Morgan 2026 Healthcare Conference. Webcasts of their presentations will be available on Amneal's Investor Relations website.
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
Amneal Pharmaceuticals announced the U.S. FDA approval of its cyclosporine ophthalmic emulsion 0.05%, a generic equivalent to RESTASIS®, for the treatment of dry eye disease. This approval highlights Amneal's expertise in complex ophthalmic formulations and sterile manufacturing, with a launch anticipated in Q1 2026. The product aims to address a significant market, given the condition affects millions and RESTASIS® generated approximately $2.0 billion in U.S. sales over the last year.
Amneal Pharmaceuticals Receives FDA Approval for Cyclosporine Ophthalmic Emulsion 0.05%, Expanding Its Leadership in Complex Ophthalmic Therapies
Amneal Pharmaceuticals has received FDA approval for its cyclosporine ophthalmic emulsion 0.05%, a preservative-free treatment for dry eye disease that will be a generic equivalent to RESTASIS. This product, supplied in single-use vials, aims to increase tear production in patients with ocular inflammation and is expected to launch in Q1 2026. This approval reinforces Amneal's expertise in complex sterile manufacturing and its growing presence in the ophthalmic and Affordable Medicines segments, targeting a market estimated at $2 billion annually.
Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) has seen a significant 25% share price increase in the last month and 51% over the past year. Despite this, its Price-to-Sales (P/S) ratio of 1.3x remains low compared to the industry average, largely due to its anticipated weak revenue growth of 7.8% over the next year against an industry projection of 24%. This suggests that the market is not convinced of its future growth potential, keeping its valuation modest.
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following FDA Approval of First Generic Omnipaque
Amneal Pharmaceuticals (AMRX) announced FDA approval for its generic iohexol injection, the first generic version of GE Healthcare’s Omnipaque, with a Q1 2026 launch expected. This entry into the $652 million market could boost Amneal's growth, though competitive pricing pressures remain a significant risk. The company is projected for substantial revenue and earnings growth by 2028, with community fair value estimates varying widely, suggesting a potential upside.
Amneal Pharmaceuticals stock hits 52-week high at $12.12
Amneal Pharmaceuticals (AMRX) stock recently reached a 52-week high of $12.12, reflecting a 43.91% one-year change and strong recent momentum with 50.88% YTD returns and a 66.9% surge over six months. The company boasts "GREAT" financial health, and analysts are bullish with price targets of $13-14, despite the stock appearing slightly overvalued. This growth is supported by better-than-expected Q3 2025 financial results, FDA approval for its generic iohexol injection, and an upgraded outlook from S&P Global Ratings.
Amneal Pharmaceuticals stock hits 52-week high at $12.12
Amneal Pharmaceuticals Inc. (AMRX) stock recently reached a new 52-week high of $12.12, reflecting a 43.91% increase over the past year and impressive year-to-date returns of 50.88%. The company boasts a "GREAT" financial health score with strong liquidity, and analysts project further upside potential, setting price targets between $13-14. This milestone follows better-than-expected Q3 2025 financial results and FDA approval for its generic iohexol injection.
Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs
Nikita Shah, EVP of Amneal Pharmaceuticals, sold $1.6 million worth of shares after exercising stock options, representing 47% of her direct holdings. While this is a significant insider sale, the company's strong Q3 revenue growth and increased full-year guidance suggest the transaction is likely related to compensation vesting rather than a loss of insider confidence. Investors are advised to consider the context of the stock's recent rally and the company's healthy fundamentals.
Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point
Amneal Pharmaceuticals (NASDAQ:AMRX) recently reported strong earnings, which were positively received by the market. The company's profit was notably reduced by US$49m due to unusual items in the last year, which are expected to be one-off and could lead to increased profit in the coming year. This suggests that Amneal Pharmaceuticals' statutory profit might currently understate its true earnings potential.
Amneal pharma exec Nikita Shah sells $1.57 million in stock
Amneal Pharmaceuticals Executive Vice President Nikita Shah sold 131,856 shares of Class A Common Stock for approximately $1.57 million on November 12, 2025. This transaction occurred around the company's 52-week high, following Shah's exercise of options to acquire the same number of shares. Amneal recently reported strong Q3 2025 financial results and received FDA approval for a generic product, indicating potential growth.
Amneal Pharmaceuticals stock reaches 52-week high at 11.89 USD
Amneal Pharmaceuticals (AMRX) stock hit a 52-week high of $11.89, showcasing a significant upward trend with a 24.78% increase over the past year and a 54.93% surge in the last six months. The company's market capitalization stands at $3.61 billion, driven by strong investor confidence and recent positive financial results, including an adjusted EPS of $0.17 and revenue of $785 million for Q3 2025. S&P Global Ratings revised its outlook for Amneal to positive, maintaining a 'B+' credit rating and projecting improved leverage.
A Look at Amneal Pharmaceuticals’s Valuation Following Strong Q3 Results and Key Product Launches
Amneal Pharmaceuticals (AMRX) recently reported strong Q3 results, including higher sales and a swing to profit, alongside new product launches in respiratory and migraine care. The company's share price has significantly outpaced the S&P 500, with a 362% three-year total shareholder return. Analysts believe AMRX is undervalued, with a fair value estimate of $13.50, due to its diversification into branded products, active pipeline, and strong growth projections, although margin expansion and regulatory pressures remain potential challenges.
Amneal Pharmaceuticals stock hits 52-week high at 9.48 USD
Amneal Pharmaceuticals Inc. Class A stock reached a new 52-week high of $9.48, reflecting investor confidence and positive market sentiment. Analysts have set price targets between $11 and $13, suggesting potential for further upside. The company also reported strong Q2 2025 earnings, with EPS exceeding expectations despite a slight revenue miss.
Amneal Pharmaceuticals stock hits 52-week high at $10.72
Amneal Pharmaceuticals stock reached a new 52-week high of $10.72, marking a 26.27% increase over the past year and a 30.55% gain in the last six months. This surge is supported by a "GREAT" financial health score and revenue growth of 9.81%. The company also reported stronger-than-expected Q3 2025 financial results, with adjusted EPS of $0.17 and revenue of $785 million.
Amneal Reports Third Quarter 2025 Financial Results
Amneal Pharmaceuticals, Inc. reported strong third-quarter 2025 financial results, with net revenue of $785 million, marking a 12% increase year-over-year. The company's Specialty segment saw growth driven by products like CREXONT® and UNITHROID®, while the Affordable Medicines segment benefited from new product launches. Amneal also updated its 2025 full-year guidance, reflecting confidence in its diversified business and product portfolio.
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strengthened Balance Sheet and Pipeline Expansion
Amneal Pharmaceuticals (AMRX) has significantly improved its capital structure through debt reduction, improved cash flow, and refinancing, alongside expanding its pipeline and securing new FDA approvals. These strategic moves have led to substantial stock price gains, prompting an analysis of whether the company remains undervalued at its current trading levels, with one valuation narrative suggesting it's 17.7% undervalued.
Amneal Pharmaceuticals stock hits 52-week high at $10.72 By Investing.com
Amneal Pharmaceuticals Inc. (AMRX) stock reached a 52-week high of $10.72, marking a 26.27% increase over the past year and a 30.55% gain in the last six months. The company's Q3 2025 financial results also exceeded expectations, with an adjusted EPS of $0.17 against a forecast of $0.14, and revenue of $785 million compared to an anticipated $769.46 million. Despite strong performance and consistent growth, InvestingPro analysis suggests the stock is slightly overvalued, with analysts setting price targets as high as $14.
Does Amneal Pharmaceuticals Still Offer Value After 36% Surge and New Product Approvals in 2025?
Amneal Pharmaceuticals has seen significant stock growth, with a 36% surge year-to-date and 419.7% over three years, prompting a valuation analysis. Simply Wall St indicates the company appears undervalued across multiple metrics, including Discounted Cash Flow and Price-to-Sales ratios, suggesting potential for further growth. The article emphasizes personalized "Narratives" for investors to connect their assumptions with financial forecasts and fair value assessments.
Amneal Pharmaceuticals (AMRX) Is Up 16.8% After Swinging to Q2 Profitability – What's Changed?
Amneal Pharmaceuticals reported a significant turnaround in Q2 2025, swinging to a US$22.42 million profit from a net loss, with sales rising to US$724.51 million. This profitability shift is attributed to effective execution and strategic product launches, such as the FDA approval of Brekiya®, a migraine treatment, aligning with the company's diversification beyond traditional generics. While forecasts project substantial revenue and earnings growth by 2028, the company still faces risks from intensive competition and U.S. revenue concentration.
